The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies ...
Health-care companies fell as traders braced for regulatory changes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback